The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
12
03
2024
accepted:
07
08
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
We present here the K9 lymphoma assay, a novel 31-gene targeted next-generation sequencing panel designed for genomic profiling of canine lymphoid neoplasms. Addressing the growing demand for advanced diagnostics in veterinary oncology, this assay enables sensitive identification of known and actionable mutations specific to canine lymphomas, while evaluating its prognostic potential to facilitate diagnosis and prognosis. Our analysis, spanning several B- and T-cell lymphoma histotypes, unveiled distinct mutational landscapes distinguishing tumors derived from immature versus mature lymphocytes. Clustering analysis revealed a shared genetic origin between diffuse large B-cell lymphoma and marginal zone lymphoma, aligning with findings in human lymphomas, with TRAF3 emerging as the most frequently mutated gene across B-cell lymphoma subtypes. Significantly, TP53 mutations demonstrated universal adverse prognostic implications across B-cell lymphomas. Additionally, SETD2 mutations contributed to shorter time-to-progression, underscoring the role of epigenetic dysregulation in B-cell tumors. In T-cell lymphomas, SATB1 and FBXW7 were frequently mutated, warranting further investigation in larger cohorts. Our findings advocate for tailored therapeutic approaches based on the genetic profile, impacting treatment decisions and outcomes in canine lymphoma management. This study provides pivotal insights bridging veterinary and human oncology, paving the way for comprehensive genomic diagnostics and therapeutic strategies in comparative oncology.
Identifiants
pubmed: 39134766
doi: 10.1038/s41598-024-69716-6
pii: 10.1038/s41598-024-69716-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18687Informations de copyright
© 2024. The Author(s).
Références
Zandvliet, M. Canine lymphoma: A review. Vet. Q. 36, 76–104. https://doi.org/10.1080/01652176.2016.1152633 (2016).
doi: 10.1080/01652176.2016.1152633
pubmed: 26953614
Valli, V. E. et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet. Pathol. 48, 198–211. https://doi.org/10.1177/0300985810379428 (2011).
doi: 10.1177/0300985810379428
pubmed: 20861499
Aresu, L. et al. Canine indolent and aggressive lymphoma: Clinical spectrum with histologic correlation. Vet. Comp. Oncol. 13, 348–362. https://doi.org/10.1111/vco.12048 (2015).
doi: 10.1111/vco.12048
pubmed: 23782432
Modiano, J. F. et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 65, 5654–5661. https://doi.org/10.1158/0008-5472.CAN-04-4613 (2005).
doi: 10.1158/0008-5472.CAN-04-4613
pubmed: 15994938
Marconato, L. et al. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: A 5-year experience in two veterinary oncology centers. J. Immunother. Cancer 7, 146. https://doi.org/10.1186/s40425-019-0624-y (2019).
doi: 10.1186/s40425-019-0624-y
pubmed: 31174615
pmcid: 6554898
Richards, K. L. et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 73, 5029–5039. https://doi.org/10.1158/0008-5472.CAN-12-3546 (2013).
doi: 10.1158/0008-5472.CAN-12-3546
pubmed: 23783577
pmcid: 3755352
Aresu, L. et al. New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica 104, e256–e259. https://doi.org/10.3324/haematol.2018.207027 (2019).
doi: 10.3324/haematol.2018.207027
pubmed: 30545928
pmcid: 6545862
Bushell, K. R. et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood 125, 999–1005. https://doi.org/10.1182/blood-2014-10-602714 (2015).
doi: 10.1182/blood-2014-10-602714
pubmed: 25468570
Elvers, I. et al. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 25, 1634–1645. https://doi.org/10.1101/gr.194449.115 (2015).
doi: 10.1101/gr.194449.115
pubmed: 26377837
pmcid: 4617960
Giannuzzi, D. et al. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. Lab Anim. 51, 191–202 (2022).
doi: 10.1038/s41684-022-00998-x
Kamps, R. et al. Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int. J. Mol. Sci. https://doi.org/10.3390/ijms18020308 (2017).
doi: 10.3390/ijms18020308
pubmed: 28146134
pmcid: 5343844
Chon, E. et al. Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs. J. Am. Vet. Med. Assoc. 261, 668–677. https://doi.org/10.2460/javma.22.11.0489 (2023).
doi: 10.2460/javma.22.11.0489
pubmed: 36862546
Wu, K. et al. Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs. NPJ Precis. Oncol. 7, 8. https://doi.org/10.1038/s41698-023-00346-3 (2023).
doi: 10.1038/s41698-023-00346-3
pubmed: 36658200
pmcid: 9852553
Wang, G. et al. Actionable mutations in canine hemangiosarcoma. PLoS One 12, e0188667. https://doi.org/10.1371/journal.pone.0188667 (2017).
doi: 10.1371/journal.pone.0188667
pubmed: 29190660
pmcid: 5708669
Megquier, K. et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol. Cancer Res. 17, 2410–2421. https://doi.org/10.1158/1541-7786.MCR-19-0221 (2019).
doi: 10.1158/1541-7786.MCR-19-0221
pubmed: 31570656
pmcid: 7067513
Wang, G. et al. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. PLoS One 15, e0229728. https://doi.org/10.1371/journal.pone.0229728 (2020).
doi: 10.1371/journal.pone.0229728
pubmed: 32210430
pmcid: 7094861
Wong, K. et al. Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma. Dis. Model. Mech. https://doi.org/10.1242/dmm.049044 (2021).
doi: 10.1242/dmm.049044
pubmed: 34296746
pmcid: 8319545
Estabrooks, T. et al. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma. Vet. Comp. Oncol. 21, 623–633. https://doi.org/10.1111/vco.12925 (2023).
doi: 10.1111/vco.12925
pubmed: 37734854
Gardner, H. L. et al. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun. Biol. 2, 266. https://doi.org/10.1038/s42003-019-0487-2 (2019).
doi: 10.1038/s42003-019-0487-2
pubmed: 31341965
pmcid: 6642146
Sakthikumar, S. et al. SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma. Cancer Res. 78, 3421–3431. https://doi.org/10.1158/0008-5472.CAN-17-3558 (2018).
doi: 10.1158/0008-5472.CAN-17-3558
pubmed: 29724721
Hendricks, W. P. D. et al. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 14, e1007589. https://doi.org/10.1371/journal.pgen.1007589 (2018).
doi: 10.1371/journal.pgen.1007589
pubmed: 30188888
pmcid: 6126841
Cozzi, M. et al. Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour. Vet. Comp. Oncol. 16, 246–252. https://doi.org/10.1111/vco.12374 (2018).
doi: 10.1111/vco.12374
pubmed: 29205839
Marconato, L. et al. Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma. Vet. J. 246, 78–84. https://doi.org/10.1016/j.tvjl.2019.02.002 (2019).
doi: 10.1016/j.tvjl.2019.02.002
pubmed: 30902194
Giannuzzi, D. et al. Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. Vet. Comp. Oncol. 18, 645–655. https://doi.org/10.1111/vco.12588 (2020).
doi: 10.1111/vco.12588
pubmed: 32154977
Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679–690. https://doi.org/10.1038/s41591-018-0016-8 (2018).
doi: 10.1038/s41591-018-0016-8
pubmed: 29713087
pmcid: 6613387
Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396–1407. https://doi.org/10.1056/NEJMoa1801445 (2018).
doi: 10.1056/NEJMoa1801445
pubmed: 29641966
pmcid: 6010183
Ilango, S., Paital, B., Jayachandran, P., Padma, P. R. & Nirmaladevi, R. Epigenetic alterations in cancer. Front. Biosci. (Landmark Ed) 25, 1058–1109. https://doi.org/10.2741/4847 (2020).
doi: 10.2741/4847
pubmed: 32114424
McDonald, J. T. et al. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9, 22693–22702. https://doi.org/10.18632/oncotarget.25209 (2018).
doi: 10.18632/oncotarget.25209
pubmed: 29854308
pmcid: 5978258
Fredholm, S. et al. SATB1 in malignant T cells. J. Invest. Dermatol. 138, 1805–1815. https://doi.org/10.1016/j.jid.2018.03.1526 (2018).
doi: 10.1016/j.jid.2018.03.1526
pubmed: 29751003
Ito, D., Frantz, A. M. & Modiano, J. F. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: Recent progress and applications. Vet. Immunol. Immunopathol. 159, 192–201. https://doi.org/10.1016/j.vetimm.2014.02.016 (2014).
doi: 10.1016/j.vetimm.2014.02.016
pubmed: 24642290
pmcid: 4994713
Simon, D. et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J. Vet. Intern. Med. 20, 948–954. https://doi.org/10.1892/0891-6640(2006)20[948:todwlu]2.0.co;2 (2006).
doi: 10.1892/0891-6640(2006)20[948:todwlu]2.0.co;2
pubmed: 16955821
Goodman, I. H., Moore, A. S. & Frimberger, A. E. Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003–2013). Vet. J. 211, 39–44. https://doi.org/10.1016/j.tvjl.2016.03.003 (2016).
doi: 10.1016/j.tvjl.2016.03.003
pubmed: 27017053
Marconato, L. et al. Prognostic value of peripheral blood and bone marrow infiltration assessed by flow cytometry in dogs with de novo nodal peripheral T-cell lymphoma receiving alkylating-rich chemotherapy. Vet. J. 303, 106057. https://doi.org/10.1016/j.tvjl.2023.106057 (2023).
doi: 10.1016/j.tvjl.2023.106057
pubmed: 38086438
Vail, D. M. et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)–a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet. Comp. Oncol. 8, 28–37. https://doi.org/10.1111/j.1476-5829.2009.00200.x (2010).
doi: 10.1111/j.1476-5829.2009.00200.x
pubmed: 20230579
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760. https://doi.org/10.1093/bioinformatics/btp324 (2009).
doi: 10.1093/bioinformatics/btp324
pubmed: 19451168
pmcid: 2705234
Van der Auwera, G. A. & O’Connor, B. D. Genomics in the cloud: Using docker, GATK and WDL in Terra (O’Reilly Media Inc., 2020).
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219. https://doi.org/10.1038/nbt.2514 (2013).
doi: 10.1038/nbt.2514
pubmed: 23396013
pmcid: 3833702
Koboldt, D. C. et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576. https://doi.org/10.1101/gr.129684.111 (2012).
doi: 10.1101/gr.129684.111
pubmed: 22300766
pmcid: 3290792
Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907. https://doi.org/10.48550/arXiv.1207.3907 (2012).
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164. https://doi.org/10.1093/nar/gkq603 (2010).
doi: 10.1093/nar/gkq603
pubmed: 20601685
pmcid: 2938201
Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814. https://doi.org/10.1093/nar/gkg509 (2003).
doi: 10.1093/nar/gkg509
pubmed: 12824425
pmcid: 168916